Madrigal Pharmaceuticals (NASDAQ:MDGL) secures $500 million senior secured credit facility with Blue Owl Capital Inc. (NYSE:OWL) for strategic growth and refinancing. The funding will support advancing the MASH pipeline, led by FDA-approved drug Rezdiffra, in Phase 3 trial for MASH cirrhosis. Madrigal aims to lead in MASH therapeutics with strong launch momentum and patent protection through 2044.

Read more at Yahoo Finance: Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion